Evidence map›Paper›PMID 34418449›Full record

ArticleEnvironmental research2022

Emerging concepts and opportunities for endocrine disruptor screening of the non-EATS modalities.

Christopher J Martyniuk, Rubén Martínez, Laia Navarro-Martín, Jorke H Kamstra, Adam Schwendt, Stéphane Reynaud, Lorraine Chalifour

Abstract read
In one paragraph

Article in Environmental research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Prioritising research on endocrine disruption in the marine environment: a global perspective.Biological reviews of the Cambridge Philosophical Society · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Inhibition of Fin Regeneration in Fathead Minnow (Environmental science & technology · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christopher J MartyniukDepartment of Physiological Sciences and Center for Environmental and Human Toxicology, College of Veterinary Medicine, University of Florida, Gainesville, FL, 32611, USA. Electronic address: cmartyn@ufl.edu.
Rubén MartínezInstitute of Environmental Assessment and Water Research, IDAEA-CSIC, Barcelona, Catalunya, 08034, Spain.
Laia Navarro-MartínInstitute of Environmental Assessment and Water Research, IDAEA-CSIC, Barcelona, Catalunya, 08034, Spain.
Jorke H KamstraInstitute for Risk Assessment Sciences, Department of Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, the Netherlands.
Adam SchwendtDivision of Experimental Medicine, School of Medicine, Faculty of Medicine and Biomedical Sciences, McGill University, 850 Sherbrooke Street, Montréal, Québec, H3A 1A2, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec, H3T 1E2, Canada.
Stéphane ReynaudUniv. Grenoble-Alpes, Univ. Savoie Mont Blanc, CNRS, LECA, 38000, Grenoble, France.
Lorraine ChalifourDivision of Experimental Medicine, School of Medicine, Faculty of Medicine and Biomedical Sciences, McGill University, 850 Sherbrooke Street, Montréal, Québec, H3A 1A2, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec, H3T 1E2, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endocrine disrupting chemicals (EDCs) are ubiquitous in the environment and involve diverse chemical-receptor interactions that can perturb hormone signaling. The Organization for Economic Co-operation and Development has validated several EDC-receptor bioassays to detect endocrine active chemicals and has established guidelines for regulatory testing of EDCs. Focus on testing over the past decade has been initially directed to EATS modalities (estrogen, androgen, thyroid, and steroidogenesis) and validated tests for chemicals that exert effects through non-EATS modalities are less established. Due to recognition that EDCs are vast in their mechanisms of action, novel bioassays are needed to capture the full scope of activity. Here, we highlight the need for validated assays that detect non-EATS modalities and discuss major international efforts underway to develop such tools for regulatory purposes, focusing on non-EATS modalities of high concern (i.e., retinoic acid, aryl hydrocarbon receptor, peroxisome proliferator-activated receptor, and glucocorticoid signaling). Two case studies are presented with strong evidence amongst animals and human studies for non-EATS disruption and associations with wildlife and human disease. This includes metabolic syndrome and insulin signaling (case study 1) and chemicals that impact the cardiovascular system (case study 2). This is relevant as obesity and cardiovascular disease represent two of the most significant health-related crises of our time. Lastly, emerging topics related to EDCs are discussed, including recognition of crosstalk between the EATS and non-EATS axis, complex mixtures containing a variety of EDCs, adverse outcome pathways for chemicals acting through non-EATS mechanisms, and novel models for testing chemicals. Recommendations and considerations for evaluating non-EATS modalities are proposed. Moving forward, improved understanding of the non-EATS modalities will lead to integrated testing strategies that can be used in regulatory bodies to protect environmental, animal, and human health from harmful environmental chemicals.

Indexed as

Endocrine DisruptorsAnimalsAnimals, WildBiological AssayEndocrine SystemHumansObesityEndocrine DisruptorsAryl-hydrocarbonEndocrine disruptionHypertensionLipidsMetabolic syndromeRetinoic acid

Identifiers

PMID34418449
PMCPMC8669078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.